Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002506 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
A Phase 4 study, sponsored by Texas Tech University Health Sciences Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03002506 is a Phase 4 study that was terminated before completion, run by Texas Tech University Health Sciences Center. The registered enrollment target is 6 participants.
The verdict
NCT03002506, a Phase 4 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will help provide information about how patients with burn handle two antibiotics (ceftolozane and tazobactam) and use that information to guide dosing recommendations for these patients. The 12 patients who complete the study will receive a single dose of 3 grams ceftolozane/tazobactam intravenously. We will collect blood and urine samples to determine how much of each antibiotic is in the body and urine at various times over a 24 hour period. This information will be used with previously published information from microbiology laboratories to perform simulations that will provide recommendations on optimal dosing recommendations of these antibiotics in patients with burns.
Interventions
- DRUG Ceftolozane/tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002506
The ClinicalTrials.gov registry entry for NCT03002506 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ceftolozane/tazobactam is the first listed.
NCT03002506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002506 about?
NCT03002506 is a clinical study titled "Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns". This study will help provide information about how patients with burn handle two antibiotics (ceftolozane and tazobactam) and use that information to guide dosing recommendations for these patients. The 12 patients who complete the study will receive a single dose of 3 grams ceftolozane/tazobactam i...
What is the current status of trial NCT03002506?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2017-08-21. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03002506?
The interventions under investigation include: Ceftolozane/tazobactam (DRUG).
Who is sponsoring clinical trial NCT03002506?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.